Health & Biotech
PharmAust Limited (ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications.
The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
In Case You Missed It: High grade antimony and sneaky takeover attempts
Health & Biotech
PharmAust eyes US orphan drug designation after successful phase 1 motor neurone disease trial
News
In Case You Missed It: Abundant spodumene crystals and solid Q3 gold production
Health & Biotech
PharmAust races for access to the US market after confirming its canine cancer treatment is safe for pooches
Health & Biotech
New CEO to take the helm as PharmAust progresses clinical studies
Health & Biotech
Results from 11 out of 12 patients in PharmAust trial point to stabilised MND progression
News
Top 10 at 10: Red Sky jumps 20pc on news of 100pc offtake deal with Viva
Health & Biotech
Preliminary evidence for MPL activity enables PharmAust to commence planning a Phase 2 trial in motor neurone disease
Health & Biotech
PharmAust MPL is well tolerated in three MND/ALS patient cohorts
Health & Biotech
PharmAust nears end point of its Phase 2 dog cancer trial and the outlook seems sunny
News
In Case You Missed It: A management shuffle, lithium and some rare earths
Health & Biotech
PharmAust secures more proof of MPL’s efficacy in stopping MND progression
Health & Biotech
Louie the Beagle has lived comfortably with cancer for the past year, thanks to PharmAust
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
Health & Biotech
PharmAust’s preliminary trial data indicate slowing or stopping the progression of motor neuron loss that causes MND
News
Closing Bell: ASX scores in closing minutes of EOFY trade to finish in the green after volatile day
Health & Biotech